Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Positive late-stage results still fell short of investor expectations, and the selloff also pushed Merck and Pfizer lower.
10 Articles
10 Articles
Moderna fell 7.1 percent on New York stock exchanges on Friday. The pharmaceutical company had already lost nearly 18 percent of its market value the day before following leaked results regarding a potential new skin cancer vaccine from the company. Although the vaccine, which Moderna developed together with industry peer Merck, significantly reduces the risk of recurrence or death from skin cancer, the results fell short of investors' high expe…
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
The post Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip appeared first on 24/7 Wall St.. Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) came back positive, yet the selling hasn’t stopped. Those numbers landed short of the loftiest hopes built into a long rally. Moderna stock is down 4% to $193.62 in morning trading. The move extends an 18…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
